Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

al of Atu027 in patients with solid tumours. Interim results from the trial were announced at the annual meeting of the American Society of Clinical Oncology ('ASCO') in June 2012. The results demonstrated that 10 of the 33 patients treated with Atu027 achieved stable disease at study end (three months after treatment initiation). Patient recruitment into this trial is now complete.  A total of 34 patients have been recruited into the trial which is expected to finish in July 2012 with results available shortly thereafter. To date, Atu027 has been shown to be safe and well tolerated.  The Company plans to use proceeds from this Fundraising to conduct a small Phase Ib trial using Atu027 in combination with a chemotherapy regimen, and subject to the results of this study and any necessary preclinical work, conduct a small Phase IIa trial.

Atu111

Atu111, for the treatment of acute lung injury, is the Company's most advanced drug development candidate

outside oncology. Unlike Silence oncology drug candidates, Atu111 combines Silence' DACC drug delivery system with AtuRNAi. The target for this RNAi therapeutic is undisclosed. However, pre-clinical models using the DACC delivery system have shown sustained knockdown of up to three weeks in the lung endothelium. Silence recently completed proof-of-concept studies in a pre-clinical model of acute lung injury demonstrating  encouraging results using Atu111. Based on these results, Silence plans to conduct further studies in different pre-clinical models of acute lung injury.

Liver projects

Diseases including liver fibrosis and liver cancer continue to be areas of high unmet medical need and their high prevalence in Asia mean they are of increasing interest to pharmaceutical companies. Silence has developed a novel delivery system known as DBTC that enables highly specific delivery of siRNA molecules to cells of the liver including hepatocytes. Silence therefore recently initi
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... International, a leading provider of regulatory compliance, quality systems, analytical testing, education ... a consulting firm with expertise in medical device products/processes development, design control, ...
(Date:9/2/2015)... ... 2015 , ... The wet form of macular degeneration, although ... growth factor agents given by injection into the eye. Dry macular degeneration (AMD) ... for the many millions diagnosed with it. AMD usually starts in older age ...
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee ... for,the benefit of creditors, announced today that ... sold at a sealed bid auction on ... hydrophobic thermoplastic,polymers, Spheromers(TM), have superior conventional hydrophilic,bioadhesive ...
... InNexus,Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF, ... next,generation of monoclonal antibodies based on its Dynamic ... Board of Directors., Mr. Warden was a ... his 23 years of practice, he has represented ...
... Calif., Sept. 9 Energy crop company,Ceres, Inc. ... and high-biomass sorghum hybrids with Range Fuels, Inc. ... the site of Range Fuels,commercial-scale cellulosic ethanol plant, ... southeast of Atlanta., While wood residues will ...
Cached Biology Technology:Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System 2InNexus Biotechnology Strengthens Patent Team With New Leadership 2Ceres Trials Energy Crops at Georgia Biofuel Facility 2Ceres Trials Energy Crops at Georgia Biofuel Facility 3
(Date:9/1/2015)... Sept. 1, 2015  Automation and pre-processing are ... passenger screening. This is the first step toward ... will become unintrusive. An assortment of portal scanners, ... background investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( ...
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... Queen,s University biologists are part of an international ... in a remote Arctic lake provides compelling evidence of ... "Our findings show that the last several ... years," says Neal Michelutti, a research scientist at the ...
... that biological and chemical changes occurring at a remote Arctic ... are the result of human-caused climate change, according to a ... While environmental changes at the lake over the ... natural causes of climate change -- like periodic, well-understood wobbles ...
... key to new ways to fight cancer and other ... in regulating circadian rhythm, says Liheng Shi, a researcher ... rhythm is the roughly 24-hour cycle of physiological activities ... and colleagues have had their research, currently focusing on ...
Cached Biology News:Queen's scientists on international team discover 'ecologically unique' changes in Arctic lake 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Texas A&M researchers find new mechanism for circadian rhythm 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
... bench time to just 15 minutes! The ... that can be drawn between this exciting new ... instant foods. Instant meals consumed by astronauts, ... and are reconstituted by adding water. The ...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Candida (IgA) -Ab EIA Sample Size: 5 l...
Biology Products: